Reimbursement and Pricing of Pharmaceuticals in Europe

Market access for pharmaceuticals in Europe and reimbursement of pharmaceuticals in Europe is challenging: The European pharmaceutical market is one of the most sophisticated and heavily regulated healthcare environments in the world. Unlike the United States, where market dynamics and private insurance largely dictate pricing, Europe relies on a patchwork of national healthcare systems heavily funded by public resources. Consequently, achieving regulatory approval (market authorization) from the European Medicines Agency (EMA) for the European Union or from the MHRA for the United Kingdom is only the first step in a drug's lifecycle – reimbursement and market access follow.

The primary objective of European payers is to balance timely patient access to innovative therapies with the long-term fiscal sustainability of public healthcare budgets. European countries utilize a diverse array of pricing mechanisms. One of the most prevalent strategies is External Reference Pricing (ERP). In addition, many countries employ Internal Reference Pricing (IRP). For highly innovative therapies such as advanced therapy medicinal products (ATMPs), European authorities increasingly rely on Managed Entry Agreements (MEAs).

Print copies of the Guide ‘Reimbursement and Pricing of Pharmaceuticals in Europe’, can be requested here free of charge:

E-mail: pharma@iges.com

Phone: +49-(0)30-23 08 09 0

Market Access for Pharmaceuticals in Europe

Market access in Europe encompasses the strategic process of ensuring that a pharmaceutical product is not only legally permitted to be sold, but is also structurally and financially positioned to reach the appropriate patient populations. Securing market access requires a multidisciplinary approach that bridges the gap between regulatory approval, health economics, clinical evidence, and government relations.
The journey to successful market access is fraught with commercial hurdles. A drug with a flawless regulatory profile may still fail commercially if national payers deem its price too high relative to its added clinical value. Market access timelines vary drastically across Europe. In some countries, such as Germany, immediate market access is granted upon regulatory approval, allowing commercial distribution while pricing negotiations take place.

To mitigate these barriers, early engagement with stakeholders is vital. Scientific advice sessions with health technology assessment bodies, early dialogue with payers, and the incorporation of patient-reported outcomes (PROs) into phase III clinical trials have become baseline requirements for maximizing a product's market access potential in the competitive European landscape.

EU-wide Joint Clinical Assessment (JCA) and EU-HTA

The European pharmaceutical landscape is undergoing its most profound structural shift in decades with the implementation of the European Health Technology Assessment Regulation (EU) 2021/2282, which established the framework for EU-wide Joint Clinical Assessments (JCAs). The new EU-HTA regulation aims to harmonize the clinical aspects of these assessments across all member states.
The JCA process shifts the evaluation of clinical data – specifically safety, efficacy, and relative clinical effectiveness – from the national level to a centralized European Coordination Group on HTA. It is important to emphasize that the JCA does not replace national decision-making. Non-clinical aspects, such as economic evaluations, budget impact analyses, cost-effectiveness modeling, and the ultimate decision regarding pricing and reimbursement, remain strictly under the jurisdiction of individual member states.

Phased Rollout of the JCA

The rollout of the JCA is being executed via a phased timeline:

• January 2025: Oncology medicines and advanced therapy medicinal products (ATMPs)
• January 2028: Orphan medicinal products targeting rare diseases
• January 2030: All centrally authorized medicinal products with new active substances

EU-HTA Scoping and PICO Requirements

The operational cornerstone of the new EU-wide Joint Clinical Assessment is the Scoping Process, a meticulous mechanism designed to capture the diverse clinical realities of all EU member states. The scoping process resolves this by consolidating the requirements of all member states into a unified framework known as the PICO template.

The PICO Framework Explained

P – Population

The specific patient population or sub-populations for whom the drug is indicated.

I – Intervention

The new medicine being evaluated, including its specific dosage and administration schedule.

C – Comparator

The current standard of care or existing therapies used in routine clinical practice against which the new drug must be compared.

O – Outcome

The specific clinical endpoints, such as overall survival, progression-free survival, quality of life, or safety profiles, that matter to payers.

Joint Scientific Consultations (JSC)

In the context of the EU HTA regulation, Joint Scientific Consultations (JSC) serve as a collaborative platform allowing health technology developers to seek early guidance from HTA bodies regarding evidence generation. By participating in Joint Scientific Consultations, manufacturers can align their clinical trial designs, choice of comparators, and patient endpoints with the specific expectations of European assessors.

Engaging in Joint Scientific Consultations helps companies mitigate the risk of evidentiary gaps before launching pivotal, resource-intensive clinical studies. Failure to adequately satisfy the PICO requirements in the JCA dossier can lead to an unfavorable joint assessment report, severely crippling the drug's downstream pricing and reimbursement potential at the national level.

Health Technology Assessment in Europe (HTA)

Health Technology Assessment (HTA) is a multidisciplinary process that summarizes information about the medical, social, economic, and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, and robust manner. In Europe, HTA serves as the vital scientific bridge connecting regulatory authorization with political and economic reimbursement decisions.

Clinical Assessment

The clinical assessment evaluates the added therapeutic benefit – often termed relative effectiveness – of the new drug compared to current medical practices. HTA bodies scrutinize clinical trial data to determine if the drug offers hard, meaningful clinical benefits, such as prolonged life or reduced side effects, rather than just surrogate laboratory endpoints.

Economic Evaluation and Cost-Effectiveness

The economic evaluation side of HTA introduces the concept of value for money. Many European nations utilize cost-effectiveness analysis (CEA) or cost-utility analysis (CUA). These methods calculate the incremental cost-effectiveness ratio (ICER), which quantifies the extra cost required to achieve an additional unit of health benefit, typically measured in Quality-Adjusted Life Years (QALYs).

QALY and Willingness-to-Pay Thresholds

If the cost per QALY exceeds a country's implicit or explicit willingness-to-pay threshold, the drug will likely face rejection or heavy price discounts. Other countries reject the QALY framework, opting instead for efficiency frontiers or strict clinical benefit grading systems.

Reimbursement in Germany: G-BA and AMNOG

Germany represents the largest pharmaceutical market in Europe and is historically renowned for providing rapid access to innovative medicines. The cornerstone of the German reimbursement system is the AMNOG (Arzneimittelmarktneuordnungsgesetz / Pharmaceuticals Market Reorganization Act) process, introduced in 2011.

The AMNOG Benefit Assessment Process

Under the AMNOG framework, a newly approved drug enters the German market immediately upon regulatory authorization, and the manufacturer can freely set its initial launch price for the first six months. Simultaneously, the manufacturer must submit a comprehensive benefit dossier to the G-BA (Gemeinsamer Bundesausschuss / Federal Joint Committee), supported by the IQWiG.

G-BA Benefit Rating Categories

The G-BA issues a formal resolution grading the added benefit (Zusatznutzen) into one of six categories:

• Major (erheblich)
• Considerable (betrachtlich)
• Minor (geringfugig)
• Unquantifiable (nicht quantifizierbar)
• No added benefit (kein Zusatznutzen)
• Less benefit (geringerer Nutzen)

Price Negotiation with GKV-Spitzenverband

This benefit rating serves as the foundational leverage for the next phase of the process: price negotiation. If the G-BA rules that the drug offers an added benefit, the manufacturer enters into negotiations with the GKV-Spitzenverband to determine a discounted reimbursement price (the Erstattungsbetrag), which applies retroactively from the seventh month onwards.

Recent Legislative Reforms: GKV-Finanzstabilisierungsgesetz

Recent legal updates, such as the GKV-Finanzstabilisierungsgesetz (GKV-FinanzStG), have significantly tightened AMNOG rules, shortening the free-pricing period from one year to six months and introducing stricter price discounts, particularly for combination therapies. Despite these cost-containment pressures, Germany remains a critical anchor country for global pharmaceutical launches.

Confidential Reimbursement Amounts Since 2025

Since January 2025, confidential reimbursement amounts are possible in Germany if the drug is a novel medicine being marketed for the first time and the pharmaceutical company is actively conducting research in Germany. This reduces the risk of international reference pricing pressure.

Reimbursement in France: HAS and ASMR

The French pharmaceutical market features a rigorous, centralized assessment system focused heavily on clinical value and therapeutic positioning. The primary authority responsible is the HAS (Haute Autorite de Sante / French National Authority for Health). Within the HAS, the Transparency Committee (CT – Commission de la Transparence) conducts a thorough evaluation of all new medicines.

SMR and ASMR: The Two Core Metrics

SMR – Service Medical Rendu (Medical Benefit)

The SMR assesses whether the drug provides sufficient clinical utility to justify reimbursement by social security. It considers the severity of the disease, the drug's efficacy/safety profile, its role in the therapeutic strategy, and public health impact. The SMR can be rated as major, substantial, moderate, weak, or insufficient.

ASMR – Amelioration du Service Medical Rendu (Improvement in Medical Benefit)

The ASMR measures the added therapeutic value of the drug compared to existing treatments. It is graded on a scale from ASMR I (major innovation) to ASMR V (no improvement). The ASMR score is the primary driver for price negotiations conducted with the CEPS (Comite Economique des Produits de Sante).

Price Negotiations with CEPS

A high ASMR rating (I, II, or III) grants the manufacturer a significant competitive advantage, often enabling them to secure favorable price parity with other European markets. Conversely, an ASMR V rating means the drug cannot be priced higher than its direct competitors.

Reimbursement in the United Kingdom: NICE

In the United Kingdom, specifically within England, the gatekeeper to pharmaceutical market access is the NICE (National Institute for Health and Care Excellence). Renowned globally for its pioneering work in health economics, NICE evaluates the clinical and cost-effectiveness of health technologies to ensure that the NHS allocates its fixed budget efficiently.

Cost-Utility Analysis: QALY and ICER

Unlike Germany or France, NICE evaluates drugs through a rigorous Cost-Utility Analysis. The core metric is the QALY (Quality-Adjusted Life Year). NICE calculates the Incremental Cost-Effectiveness Ratio (ICER). As a general rule, NICE considers a medicine to be cost-effective if its ICER falls below a standard threshold of £20,000 to £30,000 per QALY.

Patient Access Schemes (PAS)

To achieve a positive NICE recommendation, pharmaceutical companies routinely engage in confidential commercial negotiations. Manufacturers submit Patient Access Schemes (PAS) – typically price discounts or risk-sharing mechanisms – to effectively lower the ICER. Once NICE issues positive guidance, the NHS is legally mandated to fund the treatment within 90 days.

Reimbursement in Italy: AIFA

The market access landscape in Italy is governed by the AIFA (Agenzia Italiana del Farmaco / Italian Medicines Agency). AIFA controls the entire lifecycle of a pharmaceutical product post-EMA approval, handling everything from safety vigilance to price negotiations.

Managed Entry Agreements (MEA) in Italy

Italy is widely recognized as a global pioneer in the utilization of Managed Entry Agreements (MEAs) to manage financial uncertainty and clinical risk. For high-cost innovations, AIFA heavily implements performance-based registries.

Types of Conditional Reimbursement

• The SSN pays for the drug only if the patient achieves predefined clinical success criteria. Payment-by-Result:
• The manufacturer covers a percentage of the treatment cost for patients who fail to respond to the therapy. Risk-Sharing:
• A discounted price or free initial cycles are provided for all patients at the start of therapy. Cost-Sharing:

Regional Fragmentation: Prontuari Terapeutici Regionali

A major hurdle in Italy is regional fragmentation. After securing a national pricing agreement from AIFA and publication in the Gazzetta Ufficiale, the drug must be adopted into 21 distinct regional hospital formularies (Prontuari Terapeutici Regionali). This frequently creates significant regional disparities, delaying actual patient access.

Reimbursement in Spain: AEMPS

In Spain, the market access pathway is characterized by a clear separation between technical scientific evaluation and macroeconomic decision-making. The process initiates with the AEMPS (Agencia Espanola de Medicamentos y Productos Sanitarios / Spanish Agency for Medicines and Medical Devices).

Therapeutic Positioning Reports (IPT)

AEMPS plays an active role in market access by preparing IPTs (Informes de Posicionamiento Terapeutico / Therapeutic Positioning Reports). An IPT is a collaborative, scientific document that evaluates a new drug's clinical efficacy and safety profile relative to existing therapeutic alternatives in the Spanish healthcare ecosystem.

CIPM: Interministerial Committee on Medicines Pricing

The ultimate authority over pricing and reimbursement decisions rests with the CIPM (Comision Interministerial de Precios de Medicamentos). The CIPM evaluates the IPT, weighs the drug's budgetary impact against the national healthcare budget, and negotiates the official reimbursement price with the manufacturer.

Decentralized Access: 17 Autonomous Communities

Spain's healthcare system is highly decentralized, split across 17 Autonomous Communities that manage their own local healthcare budgets. Securing a positive CIPM national funding decision is only half the battle. Regional bodies may impose additional access restrictions, resulting in variable access timelines depending on the region.